Lutropin alfa
As of the edition of 20 October 2026, Lutropin alfa is a protein: marketed, first approved in 2000 (EU); acts on LHCGR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2004
- Kind
- Protein
- Brand name
- Luveris
- First approved
- 29 November 2000 (EU)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Merck KGaA; 2 holders in all
- Registered trials
- 27, 4 stopped early
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Hormones; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| LHCGR | Lutropin-choriogonadotropic hormone receptor | P22888 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 3 | 1 | 0 |
| Phase 1 | 4 | 3 | 1 | 0 |
| Phase 2 | 6 | 2 | 0 | 2 |
| Phase 3 | 8 | 5 | 2 | 1 |
| Phase 4 | 5 | 2 | 1 | 1 |
| All trials | 27 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Applicant and Lead sponsor of trials | 2000 to now |